Cancer Treatment Centers of America First in U.S. to Test Novel Nanotherapy for the Treatment of Lung Cancer

Share Article

CTCA and Nanospectra Biosciences announce investigational study of using nanoparticles to kill cancer tumors from the inside out.

Cancer Treatment Centers of America

The particles are engineered to convert infrared light into heat, thermally destroying the tumor while sparing any damage to healthy tissue.

Cancer Treatment Centers of America® (CTCA) has announced that it will be the first center in the U.S. to conduct a clinical trial using advanced “nanotherapy” developed by Houston, Texas-based Nanospectra Biosciences, Inc. for the investigational treatment of primary and metastatic cancerous tumors in the lung. The pilot study, approved by the FDA and the CTCA® Institutional Review Board, will allow cancer specialists at CTCA® to use AuroLase Therapy, a new concept in the treatment of solid tumors that uses a system of near-infrared energy from a laser to heat up nanoparticles that are delivered to the tumor via the blood stream. The nanoparticles, called AuroShells, are absorbed by the tumor and not healthy tissue. The particles are engineered to convert infrared light into heat, thermally destroying the tumor while sparing any damage to healthy tissue.

This clinical trial for the treatment of advanced lung tumors resulting from either primary lung cancer or metastatic tumors in the lung follows Nanospectra Bioscience’s ongoing human clinical trials in metastatic head and neck tumors and prostate cancer with the same therapy. Nanospectra, founded in 2002, has the exclusive license from Rice University to 11 issued U.S. patents related to nanoshells and nanoparticles. The trial will be conducted by Dr. Mark Lund and his colleagues in the Interventional Pulmonology department at CTCA®.

“The use of heat to destroy malignant tumors is not new to cancer care, but this technology holds the promise of offering new and exciting treatment options for tumor destruction with minimal collateral damage to adjacent tissue and structures,” said Dr. Mark Lund, Director of Interventional Pulmonology, Bronchoscopy and The Advanced Center for Lung and Thoracic Oncology at CTCA®. “We are excited about participating in this clinical trial and contributing our experiences and treatment results to others to determine the long-term viability of the treatment.”

The AuroLase Therapy process involves infusing a single dose of nanoshell particles into the patient’s blood stream via intravenous injection. After 12 to 24 hours, enough time for the particles to accumulate inside the tumor, a special laser is used to illuminate and heat the particles within the tumor. The therapy is also being studied to be used as an adjunct treatment with radiation and chemotherapy since it only affects the tumor and has few side effects.

“Cancer Treatment Centers of America® is a leading cancer care organization that is committed to improving access to investigational cancer therapies for its patients,” said John Stroh, president and CEO, Nanospectra Biosciences. “We look forward to partnering with CTCA® in order to bring our cutting edge NanoMedicine technology to more patients suffering from cancer .“

About Nanospectra Biosciences
Nanospectra Biosciences is a private company founded in 2002. Nanospectra has an exclusive license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles. While there are numerous therapeutic, diagnostic, and industrial commercial applications, Nanospectra is focused on the development of AuroLase® Therapy utilizing AuroShell® Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. For more information please visit:

About Cancer Treatment Centers of America®
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA® offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA® provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA®, go to

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrew Welhouse
Visit website